Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.
Chapel Hill, NC-based Cempra has won a $58 million contract from BARDA to develop its lead, late-stage antibiotic for bioterror threats aimed at a pediatric population.
In the first collaboration of its kind, the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority has brought on GlaxoSmithKline to help the federal agency develop new antibiotics to combat bioterrorism and growing resistance to the drugs.
Antibiotics maker Achaogen announced today that it has landed a $60 million contract option from the federal Biomedical Advanced Research and Development Authority to further the development of its drug plazomicin to treat patients with serious Gram-negative bacterial infections.
BioCryst Pharmaceuticals ($BCRX) blamed recent setbacks for the company's decision to ax 50% of its workers, according to a release this morning. Its restructuring plans come a week after BioCryst and Presidio Pharmaceuticals jettisoned a $101 million merger agreement that would have brought BioCryst new assets in the sizzling hepatitis C field.
After this latest setback, the company's chief medical officer says that it is "unlikely" that the biotech will continue development work needed for U.S. approval.
The Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services (HHS), dismissed a biotech industry proposal for using government bonds rather than contracts to fund projects to advance vaccines and other meds for conditions resulting from bioterrorism, Bloomberg reported.
Uncle Sam has ponied up another $14.5 million in funding to advance Elusys Therapeutics' experimental drug for treating patients after anthrax attacks, according to the company. And the Pine Brook, NJ-based biopharma group is working on a plan for late-stage development of the antibody drug, ETI-204 or Anthim.
Several biopharma players--including Emergent Biosolutions, GlaxoSmithKline and Novartis--landed on the winning end of contracts from the U.S. Department of Health and Human Services to develop and churn out treatments against bioterror and pandemic threats. To fund the first phase of the effort, the HHS has committed $400 million.
Today, Nabi's new strategy took shape in the form of a merger with Australia's flu drug developer Biota, which is now moving its headquarters to the U.S.